# EUS-guided ablation for pancreatic cystic lesions: An updated review

## TL;DR

This paper reviews the latest developments in using EUS-guided ablation to treat pancreatic cystic lesions, focusing on techniques and outcomes.

## Contribution

The paper provides an updated and comprehensive review of EUS-guided ablation techniques for pancreatic cystic lesions.

## Key findings

- EUS-guided ablation is a promising minimally invasive treatment for selected pancreatic cystic lesions.
- EUS-PCC and EUS-RFA differ in indications, efficacy, and safety profiles.
- Ongoing clinical research continues to refine patient selection and procedural techniques.

## Abstract

Pancreatic cystic lesions (PCLs) are a globally prevalent condition, with incidence increasing with age. The proper treatment modality for PCLs remains a controversial topic. EUS-guided ablation represents an innovative and promising minimally invasive treatment for selected PCL patients, including EUS-guided pancreatic cyst chemoablation (EUS-PCC, such as ethanol, lauromacrogol, chemotherapeutic agents, and combination therapies) and EUS-guided radiofrequency ablation (EUS-RFA). Each treatment modality varies in treatment indications, efficacy, and safety. Herein, with ongoing advancements in clinical research, we present a comprehensive, updated review of procedural techniques, patient selection, clinical outcomes, and adverse events for EUS-PCC and EUS-RFA.